AMGN
AZN
Amgen just got a whole lot louder
Amgen dropped Phase 3 results from DeLLphi-305, and the headline is the kind that makes biotech traders sit up straight: IMDELLTRA, paired with AstraZeneca’s Imfinzi, showed a statistically significant and clinically meaningful overall survival benefit versus durvalumab alone in first-line extensive-stage small cell lung cancer.
That’s not just good vibes in a lab coat. The study also cleared secondary endpoints for progression-free survival and objective response rate, which means the combo didn’t just live longer on paper — it looked better across the usual cancer-fighting scoreboard.
Why investors should care
For Amgen, this is the sort of data that can change the conversation from “interesting asset” to “potential franchise.” A positive Phase 3 readout in a tough cancer setting can boost the drug’s commercial odds, expand physician confidence, and put a bigger spotlight on tarlatamab’s place in the oncology lineup.
For AstraZeneca, Imfinzi gets another notable cameo in a combo regimen, which matters because oncology is basically the Marvel universe of partnerships: everybody wants the right ensemble cast.
Big picture
Biotech lives and dies by these moments. If follow-up regulatory and commercial steps go smoothly, today’s clinical win could matter far beyond one press release — it could help shape how doctors treat a hard-to-tackle lung cancer and how investors value AMGN’s oncology pipeline from here on out.